|AIA Konica Minolta Digital Health Accelerator||Central, Central Region, Singapore|
|Antagene||France, Limonest, Rhone-Alpes|
|Anvil Investment Associates||-|
|Architel||Dallas, Texas, United States|
|Capital Nature||Israel, Tel Aviv, Tel Aviv District|
|Divine interVentures||California, Oakland, United States|
|FinTech Growth Fund Europe GmbH & Co KG||Austria, Vienna|
|Geometry Venture Development||Istanbul, Sariyer, Turkey|
|Haochejiadao||Beijing, Beijing, China|
|Mosaic Ventures||England, London, United Kingdom|
|Navteq||Chicago, Illinois, United States|
|Novabase Capital||Lisboa, Lisbon, Portugal|
|Phatisa||Bryanston, Gauteng, South Africa|
|Rainmaker Systems||California, Campbell, United States|
|Sabre Partners||India, Maharashtra, Mumbai|
|Selenium Enterprise Management Center||China, Shanghai|
|Xiaozhan Jiaoyu||China, Shanghai|
|ZZ Capital International||-|
|26 Jul 2022||Futian District, Guangdong Province, China|
Green Bamboo Bio
|30 Jun 2022||Beijing, Beijing, China|
|$108M||16 Sep 2021||Xuanwu District, Jiangsu, China|
|14 Oct 2020||Mountain View, California, United States|
– IASO Biotherapeutics announced the completion of $108m Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
– The round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital.
– Current shareholder GL Ventures also participated.
– Since its founding in 2017, IASO Bio has raised more than $178m.
– Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.